ELICIO THERAPEUTICS I

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

31 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

16 окт 2024 07:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

17 сен 2024 07:31:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

13 сен 2024 07:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

28 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

13 авг 2024 15:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note

12 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering

28 июн 2024 08:00:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Announces Proposed Public Offering

27 июн 2024 15:05:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

27 июн 2024 15:01:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

18 июн 2024 07:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

23 май 2024 16:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates

15 май 2024 15:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

25 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

05 апр 2024 15:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

29 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Announces $6.0 Million Private Placement Financing

18 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting

06 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

05 фев 2024 07:30:00 Источник Nasdaq GlobeNewswire

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors

25 янв 2024 08:00:00 Источник Nasdaq GlobeNewswire